Discovery & Development US 2026
Hilton San Diego Bayfront, CA
.png?width=500&height=200&name=Neuroscience%20US%202026%20(Light).png "Neuroscience US 2026 (Light)")
The Power Of Partnerships: Aligning Pharma, Biotech, And Academia To Accelerate Development & Innovation
Panel Discussion• Bridging cultures and goals
• Shared resources and expertise
• Accelerating translation
• How partnerships can streamline moving discoveries from the lab to clinical development and market
Novel Neuro-Immunological Targets
Industry PresentationCNS Drug Discovery Case Study
Industry PresentationDevelopment Of Small Molecule Huntington’s Disease Therapeutics With A Novel Mechanism Of Action
Industry Presentation• Hit identification in a phenotypic screen
• Demonstration of selective degradation of mutant huntingtin and cellular disease phenotype reversal
• PK/PD relationship in preclinical mouse models
Development Of Novel Therapeutic Drugs For Neurodegenerative Diseases
Industry PresentationSmall Molecules To Mitigate Cisplatin Toxicities Including Hearing Loss
Industry PresentationDelivering Therapies Across The Blood-Brain Barrier
Panel Discussion• Developing optimized BBB models for drug discovery
• Predicting future
• Recent technological advancements & platforms
• Challenges and unities for the delivery of biopharmaceuticals
• Using nasal to brain route
Encapsulated Cell Technology: Safe, Durable, and Broadly Applicable Ophthalmic Drug Delivery
Industry PresentationEncapsulated Cell Technology is a novel drug delivery mechanism, made up of device and biologic components into a single implantable product. This implant has a robust safety profile, is highly durable, and may be applicable to a broad range of disease states.
Reinventing CNS Drug Discovery With AI And Human Brain Organoids
Industry PresentationUnderstanding The Role Of AI & Data In Neuroscience Research
Industry PresentationGenomics Technologies For Neurological Indications
Industry PresentationTransformative Gene Therapies For Treating Rare Diseases Using A Novel Plant-Based Manufacturing
Industry PresentationWhere Smart Capital Meets Science: Investing In The Next Wave Of Drug Discovery Innovation
Panel Discussion• How investors evaluate emerging drug discovery technologies
o AI in drug discovery
• What drives funding decisions in a shifting biotech market
• Where capital is flowing next
• How investor are looking at non-dilutive founding
Beyond The Hype: AI, Data & The Industry Shift In Drug Discovery R&D
Panel Discussion• How industry dynamics are reshaping pharma R&D strategy & decision-making
• Digital transformation, AI & data-driven labs of the future
• What leaders need to prioritize to turn innovation into real scientific & business impact
Women In Drug Discovery & Development
Panel Discussion• Exploring pathways to leadership, career progression, and influence for women across drug discovery and development organizations
• Addressing barriers to advancement while sharing strategies to foster mentorship, sponsorship, and greater diversity in scientific innovation and decision-making
From Innovation to Impact: Market Strategies Driving the Next Wave of Drug Delivery Technologies
Panel Discussion• What actually defines a “successful” delivery innovation in the market?
• From lab breakthrough to commercial product: where do most strategies fail?
• Pharma vs biotech vs academia: who owns the pathway to market?
• Market access and reimbursement as the real gatekeepers of innovation
New Data Tools For Taking Biomarkers To Clinical Trials
Industry PresentationSolution Provider Presentation
Solution Provider PresentationPartnerships, Platforms Or Acquisitions: What Is The Winning Model For Brain Health Innovation?
Panel Discussioncollaboration models that actually work
• When to partner vs acquire vs build internally
• Data-sharing in a competitive landscape
• Public-private partnerships in USA: success stories & failures
Regulatory Acceptance Of Human On A Chip Systems For Neurological Diseases And Conditions
Industry PresentationBridging The Translational Gap In Neurodegenerative Drug Development
Roundtable Discussion• Building more predictive preclinical programs using human-relevant models and biomarkers
• Leveraging AI to improve target prioritization, patient stratification, and clinical trial design
• Overcoming the biggest barriers to translating promising discoveries into clinical success
• What recent neuroscience programs have taught us about reducing late-stage attrition
Single-Cell And Spatial Omics Approaches For Functional Genomics In Neuroscience
Industry PresentationPrecision Nanotherapeutic Targeting of Pathological NMDA Receptor Signaling in Alzheimer’s Disease
Industry PresentationAlzheimer’s disease drug development has been limited by the difficulty of suppressing pathological neuronal signaling without disrupting normal synaptic function. We developed a nanoscale therapeutic strategy that uses steric selectivity to preferentially target extrasynaptic NMDA receptor signaling while preserving synaptic activity. In cellular and 5xFAD mouse models, this approach produced long-lasting functional and pathological benefits, including improvements in cognition, neuronal health, neuroinflammation, and amyloid-associated pathology. This presentation will discuss the scientific rationale, preclinical validation, translational challenges, and development path for this precision nanotherapeutic platform as a potential disease-modifying approach for Alzheimer’s disease
Breaking The First In Class Barrier In Small Molecule Drug Discovery
Industry PresentationThe Target Validation Frontier: Multi-Omics And AI In Drug Discovery
Panel Discussion• Standardization and integration of omics datasets across platforms and labs
• Balancing computational predictions with experimental validation
• Challenges in scaling multi-omics for high-throughput target ID
• Regulatory considerations for omics-informed drug development
• Where AI fits in multi-omics pipelines
Dealing With High Manufacturing And Product Costs In The Gene Therapy Space
Roundtable DiscussionAI Rewiring The Future Of Drug Discovery
Industry Presentation• Taking a deep dive into generative AI for molecular design to illustrate individual methods that have transformative implications
• Putting it all together – active learning and multi-property optimisation for multiple drug properties
• Using AI to integrate early and late-stage considerations – agentic AI approaches
• How do we collaborate across the industry to develop these frameworks?
Technological Advancements For The Discovery Of New Targets
Industry PresentationAstellas's TPD Strategy and Updates from the KRAS Degrader Pipeline
Industry PresentationAn overview of Astellas’ targeted protein degradation strategy and portfolio, highlighting recent progress from the KRAS degrader ASP3082 and the development of our pan-KRAS degrader program ASP5834.
AI & In Silico Tools In Formulation Development
Roundtable DiscussionThe Degrader & Glue Landscape In 2026
Industry PresentationAdvancing Multimodal Omics Data In Drug Discovery
Industry PresentationFrom Screening to Pharmacology: Optimization of Molecular Glue Degraders
Industry PresentationChallanges Of Adopting NAMs: Regulatory & Technical Bottlenecks
Roundtable Discussion• Navigating regulatory uncertainty, validation standards, and industry confidence when integrating NAMs into development pipelines
• Overcoming technical hurdles including model reproducibility, data translation, scalability, and cross-platform comparability
Solution Provider Presentation
Solution Provider PresentationThe Use Of Quantum Mechanics In The Future Of Drug Discovery
Roundtable Discussion• Implementing AI to aid in generative design
• Looking to the future
Sponsor Presentation
Solution Provider PresentationSubmission required
Solution Provider Presentation
Solution Provider PresentationCritical Attributes For Successful mRNA Based Drug Products
Roundtable Discussion• What are critical elements for drug substance?
• What makes a good delivery system?
• How sustainable can mRNA-based drug products be?
Afternoon Break & Refreshments
Lunch Break
Morning Break & Refreshments
Close of Day One & Networking Drinks Reception
Lunch Break
End of Event
Morning Break & Refreshments
AI/ML, Specializing In Omics & Systems Biology
Industry PresentationHow Early Should Developability And Drug Delivery Considerations Influence Target Selection And Lead Optimization Decisions?
Roundtable Discussion• What risks emerge when delivery and developability are addressed too late in the discovery process?
• Should delivery feasibility be a formal criterion when prioritizing targets?
• How can discovery and development teams collaborate earlier to improve program success rates?
Multi-Omics & Predictive Models
Industry PresentationFrom Discovery to Delivery: Turning Scientific Innovation into Commercial Success
Roundtable Discussion• What separates promising science from commercially viable innovation?
• Common pitfalls in translating research into therapeutics
• Building collaborations between academia, biotech, and pharma
• How startups can position themselves for investment and strategic partnerships
Delivery-Driven Innovation: Unlocking The Potential Of Next-Generation Therapeutics
Keynote• When delivery—not the molecule—is the bottleneck
• Overcoming barriers across peptides, CNS therapies & infectious diseases, and emerging modalities
• From AI to clinical use
No sessions found matching your filters.